Lupus Trial, Recruiting NCT02954939 Sponsor: The University of Hong Kong Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT02954939
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed through a biopsy with a specific type of lupus-related kidney disease (called Class III, IV, or V lupus nephritis), and who are currently showing signs of active kidney inflammation, such as significantly increased protein in their urine or a notable decline in kidney function compared to their previous baseline levels.
  • People who are willing to give their consent to participate in the trial.

Who may not be able to join:

  • People who have taken certain immune-suppressing medications known as calcineurin inhibitors or proliferation signal inhibitors (confirm with trial site for specific drug names) within the past 3 months.
  • People who have received a type of treatment called biologic therapy — for example, rituximab or abatacept — within the past 12 months.
  • People who are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 22554385

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2017
Est. completion
31 December 2028

Where this trial is recruiting

Hong Kong

Primary endpoints

Lymphocyte subset profile (CD8+ T cells, CD4+ Th1, Th2, Th17 & Treg), Naïve & memory B cells, plasma cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov